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Animal studies have shown that electroacupuncture (EA) at Zusanli (ST-36) and Zhongwan (CV-12) acupoints reduces plasma
glucose concentrations in rats with type II diabetes. However, whether EA reduces plasma glucose levels in type I diabetes is still
unknown. In this study, we explore the various non-insulin-dependent pathways involved in EA-induced lowering of plasma
glucose. Streptozotocin (STZ) (60mgkg−1, i.v.) was administered via the femoral vein to induce insulin-dependent diabetes
in non-adrenalectomized and in adrenalectomomized rats. EA (15Hz) was applied for 30min to bilateral ST-36 acupoints
after administration of Atropine (0.1mgkg−1 i.p.), Eserine (0.01mgkg−1 i.p.), or Hemicholinium-3 (5μgkg −1 i.p.) in non-
adrenalectomized rats. Rats administered acetylcholine (0.01mgkg−1 i.v.) did not undergo EA. Adrenalectomized rats underwent
EA at bilateral ST-36 acupoints without further treatment. Blood samples were drawn from all rats before and after EA to measure
changes in plasma glucose levels. Expression of insulin signaling proteins (IRS1, AKT2) in atropine-exposed rats before and after
EA was measured by western blot. Atropine and hemicholinium-3 completely blocked the plasma glucose lowering eﬀects of EA,
whereas eserine led to a signiﬁcant hypoglycemic response. In addition, plasma glucose levels after administration of acetylcholine
were signiﬁcantly lower than the fasting glucose levels. In STZ-adrenalectomized rats, EA did not induce a hypoglycemic response.
EA stimulated the expression of IRS1 and AKT2 and atropine treatment blocked the EA-induced expression of those insulin
signaling proteins. Taken together, EA at the ST-36 acupoint reduces plasma glucose concentrations by stimulating the cholinergic
nerves.
1.Introduction
Diabetes is an important public health issue worldwide.
TraditionalChinesemedicinetreatmentsfordiabetesinclude
electroacupuncture (EA), syndrome diﬀerentiation and Chi-
nesemassage(Tuina)[1–4].EAandTuinanotonlydecrease
plasma glucose levels, but also stimulate the cardiovascular
system, the neuroendocrine system and the digestive system
to either directly or indirectly regulate plasma glucose [5–7].
Methods for controlling plasma glucose levels in patients
with diabetes mellitus (DM) include diet control, exercise
and medication. While medical treatment is convenient
and eﬀective, certain treatments can lead to serious side
eﬀects [8, 9]. Patients with poorly controlled non-insulin-
dependent, type II DM who frequently use oral hypo-
glycemic agents often present with unstable plasma glucose
levels.Inaddition,insulinresistanceduetolong-terminsulin
usage is common among patients with insulin-dependent
type I DM. Researchers have, therefore, searched for mild
or complementary treatment methods with no side eﬀects
to increase insulin sensitivity [2, 5, 6, 10]. Studies on EA
treatment of diabetes in animal models have shown that
EA leads to a reduction in plasma glucose levels by pro-
moting insulin production and improves insulin sensitivity2 Evidence-Based Complementary and Alternative Medicine
by inducing secretion of endogenous β-endorphin. Studies
have also shown that stimulating the CV-12, CV-4 and
ST-36 acupoints with a speciﬁc frequency on both sides
of rats signiﬁcantly reduces their plasma glucose levels [5,
11]. Stimulation of acupoints results in signiﬁcantly greater
plasma glucose lowering eﬀects than stimulation of adja-
cent non-acupuncture points [5]. Researches exploring this
mechanism discovered that the insulin secretion encouraged
by EA originates from endorphin stimulation, and that
suﬃcient amounts of the opioid receptor binding blocker
naloxone (1mgkg−1, i.v.) inhibits the EA-induced plasma
glucose lowering eﬀect [5]. Lin et al. showed that 15Hz
EA at the CV-12 acupoint in adrenalectomized rats resulted
in reduced plasma glucose levels [12]. A relative study
showed that a stimulation frequency of 2Hz have a minor
plasma glucose lowering eﬀect [13]. Lin et al. concluded that
multiple sources of endogenous opioid peptide participate in
the hypoglycemic eﬀect of EA (15Hz) stimulation at the CV-
12 acupoint [12]. Researchers compared the plasma glucose
lowering eﬀect of low frequency (2Hz) EA stimulation at
the ST-36 acupoint with that at the CV-12 acupoint and
foundthattheST-36acupointwasmoreeﬀectiveinreducing
plasma glucose levels. Studies have repeatedly observed that
eﬀect in adrenalectomized rats [14]. It has been shown
that the hypoglycemic eﬀect of low frequency (2Hz) EA
stimulation at the ST-36 acupoint in adrenalectomized rats
was not attenuated by naloxone treatment [15]. This ﬁnding
implies that the glucose lowering eﬀects of 2Hz EA applied
to ST-36 acupoints do not involve the endogenous opioid
peptide mechanism only. Whether or not the parasympa-
thetic nervous system participates in the plasma glucose
loweringeﬀectofEAisaninterestingquestion.Acetylcholine
(Ach)aﬀectsandrelaxesvascularsmoothmusclesandlowers
blood pressure. This occurs mainly through binding to the
M3 receptor, which results in an increase in intracellular
Ca2+ levels, which in turn leads to eNOS activation and
NOproduction.Theparasympatheticnerveblockeratropine
blocks muscarinic receptors and directly competes with
Ach for the M3 receptor. The nerve blocker hemicholin-
ium (HC-3) represses the choline re-uptake channel of
cholinergic nerves to directly repress Ach production instead
of acting upon the nerve transmission system [16]. The
ChinesescholarZhaoregulatedtheparasympatheticnervous
system and eNOS expression using sheep red blood cell
(SRBC) to induce an immune response and HC-3 blocker
to test the role of the parasympathetic nervous system
in immune system regulation induced by EA. Zhao used
the lymphocyte transformation test (LTT) and measured
interlukin-2 (IL-2) activity to evaluate whether the EA-
induced immune system regulatory eﬀects are due to the
release of Ach by parasympathetic nerves [17]. Hsieh et al.
tested the eﬀects of low frequency (2Hz) and high frequency
(100Hz) EA stimulation at the ST-36 acupoint on heart
rate and skin temperature in humans and found that high-
f r e q u e n c yE As t i m u l a t i o nl e dt oar e d u c t i o ni nh e a r tr a t e
by activating parasympathetic nerves [18]. Previous studies
have shown that EA has plasma glucose lowering eﬀects in
non-insulin-dependent types; however, the plasma glucose
lowering eﬀects and the mechanisms by which EA induces
ah y p o g l y c e m i ce ﬀect in insulin-dependent types is not well
understood.
Although acupuncture is not suitable as a long-term
treatment for diabetes, it may be suitable as a short-
term intervention in patients with unstable plasma glu-
cose control [6, 19, 20]. Previously, we explored various
insulin-dependent pathways through which EA induces
hypoglycemia [5]. In this study, we explore the various
non-insulin-dependent pathways involved in EA-induced
lowering of plasma glucose.
2. Methods
2.1. Animal Models. Normal male Wistar Rats weighing
∼250–350g and aged 8–10 weeks were purchased from
the BioLASCO animal center. After a 1-week adaptation
period, animals were randomly divided into two groups.
In Group I, insulin-dependent diabetes was induced by
administration of streptozotocin (STZ) (60mgkg−1, i.v.) via
the femoral vein on the third day of a 3-day fasting period as
described previously [11, 21]. In Group II, rats underwent
bilateral adrenalectomy. After a 3-day recovery period,
insulin-dependent diabetes was induced by administration
of STZ (60mgkg−1, i.v.) via the femoral vein as previously
described [12, 13]. Animals were housed in plexiglass cages
at a constant room temperature of 22 ±2
◦Cw i t har e l a t i v e
humidity of 65 ± 5%. Rats were fed standard rat chow
and were given free access to water. Animals were treated
in accordance with the National Institute of Health (NIH)
Guide for the Care and Use of Laboratory Animals, and the
study protocol was approved by the ethics committee of the
China Medical University, Taichung, Taiwan.
2.2. EA. Acupoints were located according to body-length
measurement as described elsewhere [22]. The ST-36 acu-
point was located on the anterior tibia muscle approximately
upper 1/6 to the length of lower leg below the knee. Bilateral
ST-36 acupoints were punctured in a vertical and deep
manner with 1.27-cm, 32-gauge acupuncture needles. After
a 5-min needling period, EA was performed for 30min at
a frequency of 15Hz and an amplitude of 10mA using a
HANS LY257 acupoint and nerve stimulator (Healthtronics,
Singapore).
2.3. Plasma Glucose Assay. Animals were anesthetized using
pentobarbital (40mgkg−1 i.p). Approximately 0.3–0.5mL of
bloodwasobtainedfromafemoralveinusinga1-mLsyringe
containing heparin. The collected blood was introduced into
eppendorﬀ tubes, lightly shaken and then stored on ice.
Following centrifugation at 21880×g for 5min, a Glucose
UV reagent (Raichem, USA) was added to test the amount of
biological index glucose contained in the serum. The content
was measured using a fully automatic biochemical analyzer
(Roche COBAS-MIRA-PLUS, USA).
2.4. Experimental Protocol
2.4.1.ElectricalAcupunctureHypoglycemicExperiment. STZ-
induced diabetic rats (n=16) were randomly divided intoEvidence-Based Complementary and Alternative Medicine 3
the EA group (N =8) or the control group (N =8). Animals
in the EA group were anesthetized and then subjected to
EA for 30min as described in the Methods section. Rats in
the control group were anesthetized but did not undergo
EA. Blood was extracted for glucose testing prior to the
experiment and 30min after the experiment as previously
described.
2.4.2. Examination of EA Impact on Glucose Mechanisms.
Atropine Experiment: Atropine 0.1mgkg−1 was injected into
the abdomens of 12 STZ-induced diabetic rats 30min prior
to the experiment. The 12 rats were randomly and equally
divided into the EA group or the control group. Blood was
extracted for glucose testing prior to the experiment and
30min after the experiment.
Eserine Experiment: Eserine 0.01mgkg−1 was injected
into the abdomens of 12 STZ-induced diabetic rats 30min
prior to the experiment. The rats were then randomly
divided into the EA group (N =6) or the control group
(N =6). Blood was extracted for glucose testing immediately
before and 30min after the experiment.
Hemicholinium (HC-3) Experiment:H C - 3( 5 μgkg −1)
was injected into the abdomens of 12 STZ-induced diabetic
rats 30min prior to the experiment. The 12 rats were then
randomly and equally divided into the EA group or the
controlgroup.Bloodwasextractedforglucosetesting30min
before and 30min after the experiment.
Ach Experiment: This experiment was performed on
six STZ-induced diabetic rats. Blood was extracted from
anesthetized animals 30min prior to the administration of
Ach 0.01mgkg−1 i.v. EA was not performed. Blood was
extracted for glucose testing 0, 30 and 60min after the
beginning of the experiment.
EA in Adrenalectomized Rats: A total of 12 STZ-induced
diabetic rats that had undergone adrenalectomy were ran-
domly divided into the EA group (N =6) or the control
group without EA (N =6). Blood was extracted for glucose
testing 30min before and 30min after the experiment.
2.4.3. Western Blot Assay. Fasting STZ rats (n=12) were
randomly divided into EA or non-EA groups. The other
fasting STZ rats (n=12) were randomly divided into the
EA or non-EA group 30min after treatment with atropine
0.1mgkg−1, i.p. At the end of treatment (30min) in
each group, portions of the gastrocnemius muscles were
taken as samples for analysis of insulin signaling proteins
(IRS1, AKT2). The samples were homogenized in buﬀer
solution before centrifugation at 16440×g. The obtained
supernatant was used to estimate the amount of protein
using an assay kit (Bio-Rad Laboratories, CA, USA). The
supernatant (protein) was added to a 4×loading dye and
boiled for 15min at 95◦C for denaturing. This process
produced a separating (8%) and stacking gel. Then, protein
(90μgmL −1) in the buﬀer solution was loaded into each
well for electrophoresis. Proteins were electrophoretically
transferred to polyvinylidene diﬂuoride membranes at 4◦C.
The membranes were then blocked with 5% nonfat dry
milk in phosphate buﬀered saline (PBS) for 1h at room
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Figure 1: Hypoglycemic eﬀects of ST-36 EA in STZ rats: EA
represents fasting for 12h and EA treatment for 30min; non-
EA represents the non-EA control group; comparison of plasma
glucose levels was performed by self-pair t-test, ∗∗P<. 01.
temperature and incubated with speciﬁc primary antibodies
(Santa Cruz Biotechnology, Inc., CA, USA). After washing
the membranes in a buﬀer containing 0.1% Tween 20 in
1×PBS, blots were incubated with a horseradish peroxidase-
linked speciﬁc second antibody (Santa Cruz Biotechnology,
Inc.) followed by enhanced chemiluminescence detection
using ECL reagent plus (PerkinElmer Life Sciences, Inc.,
USA). Band intensities were quantiﬁed by densitometry to
observe the target proteins. β-actin served as a loading
control.
2.5. Statistical Analysis. The experimental results for each
g r o u pa r ee x p r e s s e di nm e a n s ±SEM; t-test and ANOVA
statistical analyses were performed. Statistically signiﬁcant
diﬀerences were set at P<. 05.
3. Results
3.1. Hypoglycemic Eﬀect. EA (15Hz) was applied to bilateral
ST-36 acupoints in eight STZ-induced diabetic rats. As seen
in Figure 1, there was a signiﬁcant decrease in mean plasma
glucose levels before EA (418±82mgdL−1)a n d3 0m i na f t e r
EA (372 ± 77mgdL−1)( n=8, P<. 01). There were no
signiﬁcant diﬀerences in mean plasma glucose levels in the
control(non-EA)group(range447±69to420±61mgdL−1;
P>. 05).
3.2. The Inﬂuence of Atropine, HC-3 and Eserine. Atropine
(0.1mgkg−1 i.p.) and HC-3 (5μgkg −1 i.p.) blocked the
hypoglycemic eﬀects of 15Hz EA performed on the ST-
36 acupoint. Thirty minutes following treatment, mean
plasma glucose levels were 413 ± 29mgdL−1 in the atropine
group and 510 ± 109mgdL−1 in the HC-3 group. After EA
stimulation, mean plasma glucose levels had decreased by
1±4% to 408±32mgdL−1 in the atropine group and by 3±
7% to 494 ± 106mgdL−1 in the HC-3 group. There were no
signiﬁcantdiﬀerencesbeforeandafterEAtreatmentineither4 Evidence-Based Complementary and Alternative Medicine
Table 1:Inﬂuenceofatropine,eserineandHC-3onplasmaglucose
levels in STZ rats that underwent EA treatment at ST-36.
Group (n=6) Before After HGA%
Atropine+EA 413±29 408±32 –1±4
Atropine 480±51 480±54 0±2
Eserine+EA 406±55 331±57∗∗ –19±6#
Eserine 460±111 417±105 –9±6
HC-3+EA 510±109 494±106 –3±7
HC-3 491±61 471±50 –4±4
The levels of plasma glucose are expressed as mean±SEM (mgdl−1),
n: sample number; atropine: atropine 0.1mgkg−1 i.p. treatment;
atropine+EA:atropine0.1mgkg−1 i.p.treatmentpriortoEA;eserine+EA:
eserine 0.01mgkg−1 i.p. treatment prior to EA; HC-3: HC-3, 5μgkg −1
i.p. treatment; Before: plasma glucose levels 30min following medicinal
treatment; After: plasma glucose levels following 30min of EA treatment
to ST-36; HGA%: hypoglycemic activity; comparison of before and after
EA treatment by self-pair t-test ∗∗P<. 01 versus before; Student’s t-test
#P<. 05 versus the control group.
group. In addition, there were no signiﬁcant diﬀerences in
mean plasma glucose levels after injection with atropine or
HC-3 in the control group (P>. 05) (Table 1). Conversely,
15Hz EA stimulation in STZ-induced diabetic rats treated
with eserine (0.01mgkg−1 i.p.) led to a reduction in mean
plasma glucose levels. Mean glucose levels were 406 ±
55mgdL−1 followingeserinetreatmentand331±57mgdL−1
30minafterEAtreatment,representingadecreaseof19±6%
(n=6). The diﬀerence in mean values before and after EA
was signiﬁcant (P<. 01).
3.3. The Eﬀe c to fA c ho nS T ZR a t s .Plasma glucose values
were measured in STZ-induced diabetic rats before and after
administration of Ach (0.01mgkg−1 i.v.). The mean fasting
plasma glucose level was 491 ± 47mgdL−1 before treatment
and 408 ± 71mgdL−1 after 60min treatment with Ach,
representing a decrease of 18 ± 10% (n=7). The diﬀerence
between plasma glucose levels before and after treatment was
signiﬁcant (P<. 05).
3.4. The Impact of Adrenalectomy on EA. EA (15Hz) was
applied to both ST-36 acupoints in STZ-adrenalectomized
rats. Plasma glucose levels were initially 507 ± 39mgdL−1,
while plasma glucose levels following EA were 494 ±
63mgdl−1, representing a decrease of 3 ± 6% (n=6). The
diﬀerence in mean plasma glucose levels before and after
EA was not signiﬁcant (P>. 05). In addition, there were
no signiﬁcant diﬀerences in mean hypoglycemic activity
betweenSTZ-adrenalectomizedratswithEAandwithoutEA
stimulation (Table 2, P>. 05).
3.5. EA-Induced Expression of Insulin Signal Proteins. The
levelsofIRS1andAKT2proteinexpressionweresigniﬁcantly
lower in the non-EA group than in the EA group. There
were no signiﬁcant diﬀerences in IRS1 and AKT2 expression
between the EA and non-EA groups that had been adminis-
tered atropine (Figure 2).
Table 2: Hypoglycemic response to EA in STZ-adrenalectomized
rats.
Group (n=6) Before After HGA%
ADX-EA 507±39 494±63 –3±6
ADX-non EA 460±75 446±78 –3±3
The level of plasma glucose are expressed as mean±SEM (mgdL−1), n:
samplenumber;ADX-non-EA:adrenalglandswereremoved+STZinduced
but did not undergo EA; ADX-EA: adrenal glands were removed+STZ
induced, followed by EA; before: before EA; after: after EA treatment at ST-
36; comparison of plasma glucose levels before and after EA by self-pair t-
test statistical analysis.
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Figure 2: Eﬀect of EA and atropine on the expression of muscular
insulin signaling proteins. All signaling protein values were calcu-
lated as a ratio of signal protein to actin. The ratios were compared
within the groups. Signal: signal protein/actin ratio, STZ group:
the STZ-induced diabetic rats were treated with normal saline as
a control, STZ+Atro group: the STZ-induced diabetic rats were
treated with atropine 0.1mgkg−1 for 30min before EA and non-
EA. The Student’s t-test was used to compare the means between
the EA and non-EA groups, ∗∗P<. 01 was considered statistically
signiﬁcant.
4. Discussion
We found that EA stimulation at the ST-36 acupoint
for 30min resulted in a signiﬁcant reduction in plasma
glucose levels in STZ-induced diabetic rats. These results
are consistent with those reported by Lee [23]a n dC h a n g
[11] that indicated acupuncture and EA performed on ST-
36 acupoints lowered plasma glucose levels in type I diabetic
animal models. We did not evaluate the eﬀect of EA at non-
acupoints in the study because a previous study showed
that EA stimulation of the zhongwan acupoint resulted in
a more signiﬁcant plasma glucose lowering eﬀect than EA
stimulation at non-acupoints [5]. Thus, we concluded that
the hypoglycemic eﬀect of EA stimulation at acupoint is not
only due to activation of 5 -AMP-activated protein kinase
[24] caused by the contraction of electrically stimulated
muscle, but also relative with stimulating diﬀerent sites ofEvidence-Based Complementary and Alternative Medicine 5
acupoint that may more eﬀective than the site of non-
acupoint according to the meridian theory of traditional
Chinese medicine.
This study examined whether the hypoglycemic eﬀect of
15Hz EA at the ST-36 acupoints in STZ-induced diabetic
rats is mediated by the cholinergic nerve. A diagram of
the hypothetical mechanism is depicted in Figure 3.W e
ﬁrst experimented with the cholinergic nerve-blocking agent
atropine. Our ﬁndings show that atropine (0.1mgkg−1 i.p.)
completely blocks the hypoglycemic eﬀect of 15Hz EA
stimulation at the ST-36 acupoints in STZ-induced diabetic
rats, which implies that the cholinergic nerve plays a role.
TheseresultsareconsistentwiththosereportedbyPatel[25],
who found that the parasympathetic nerves in diabetic rats
play an important role in hypoglycemia. Parasympathetic
nerves, such as cholinergic nerves secrete Ach. In order to
investigate whether the plasma glucose lowering eﬀects of
EA are mediated by the cholinergic nerves, we used the
acethylcholinesterase (AchE) inhibitor eserine as a cholin-
ergic agonist to induce Ach accumulation in rats prior to
EA stimulation. We found that EA stimulation at the ST-
36 acupoint 30min after injection of eserine (0.01mgkg−1
i.p.)resultedinasigniﬁcantdecreaseinmeanplasmaglucose
levels. In addition, plasma glucose levels dropped signiﬁ-
cantly after direct injection of Ach (0.01mgkg−1 i.v.) into
the femoral vein, further demonstrating that Ach controls
plasma glucose levels. As a drug that indirectly inhibits
choline reuptake, HC-3 reduces Ach concentration between
synapses [26, 27]. In doing so, HC-3 inhibits cholinergic
nerve activity. We found that HC-3 (5μgkg −1 i.p.) blocks the
hypoglycemic eﬀects of EA stimulation at ST-36 acupoints in
diabetic rats.
In this study, we examined the role adrenal glands play
in mediating the hypoglycemic eﬀect of EA stimulation. We
found that EA did not result in a signiﬁcant decrease in
mean plasma glucose levels in STZ-adrenalectomized rats.
Therefore, our ﬁndings indicate that hypoglycemic eﬀect
of EA is not only mediated by the cholinergic nerves but
also by the adrenal glands (Figure 3). Western blot assay
detected the expression of the insulin signaling proteins
IRS1 and AKT2 in muscle tissue taken from rats that had
been stimulated by EA for 30min; however, atropine treat-
ment attenuated the expression of those signaling proteins
(Figure 2).
Parasympathetic activity mainly eﬀects insulin secretion
[28]; however, insulin secretion is impaired in STZ-induced
diabetic rats, which leads to high plasma glucose lev-
els. Hyperglycemic stress activates a non-insulin-dependent
pathway for glucose uptake in STZ rats. Cholinergic nerve
stimulation by EA may play a role in that pathway by
triggering the release of proteins involved in the insulin-
signaling cascade, such as insulin-like growth factor and β-
endorphin [13, 29]. Relative studies have also shown the
non-insulin-dependent hypoglycemic eﬀect in the μ-opioid
r e c e p t o ra g o n i s tt r a m a d o l[ 21] and mediation of the protein
kinase C (PKC) in μ-opioid receptor signaling for glucose
uptake in myoblast C2C12 cells [30]. Whether or not the
eﬀects of EA are mediated by the adrenal glands in STZ rats
deserves further study.
EA
Colinergic
nerve
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Medulla
Cortex
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Pancreas
β-cell
Insulin Type 2
Type 1
(+) (−)
Target organs
ex: muscle
(glucose uptake)
Figure 3: Hypoglycemic eﬀect of EA in diﬀerent types of DM. The
gray block and arrow indicate the main pathway of the present
study; the open arrows summarize the pathway suggested from
previousstudyinnon-insulin-dependentDM(type2)[5];thesolid
thin arrow indicates the direction of stimulation. Type 1: insulin-
dependent DM; type 2: non-insulin-dependent DM; AG: adrenal
gland; EOPs: endogenous opioid peptides; (+) (–): bilateral zusanli
acupoints(ST-36)connectedtothepositiveandnegativepoleofthe
EA apparatus.
Our ﬁndings indicate that EA (15Hz) at the ST-
36 acupoint induces a hypoglycemic response in STZ-
induced diabetic rats by stimulating the cholinergic nerves
and involving adrenal glands, which in turn stimulate the
expression of insulin signaling proteins.
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